drugset
drugset / Trial / NCT04764851

Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates

NCT04764851 ↗

Phase 1 Terminated 30 enrolled Emalex Biosciences Inc. Nuventra, Inc. · collabSyneos Health · collab
Non-randomizedParallel-groupOpen-labelBasic science

Summary

This is a single center, open-label, fixed sequence Phase 1, drug-drug interaction (DDI) study in healthy subjects.

Timeline

Start
2021-02-18
Primary completion
2021-04-02
Completion
2021-05-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule 100 ug Oral
Subject Bupropion Small molecule 100 mg Oral
Subject Caffeine Small molecule 200 mg Oral
Subject Dabigatran Unknown 375 ug Oral
Subject Dextromethorphan Unknown 10 mg Oral
Subject Ecopipam Small molecule 2 mg/kg Oral
Subject Midazolam Small molecule 1 ug Intravenous
Subject Midazolam Small molecule 10 ug Oral
Subject Omeprazole Other / unclassified 40 mg Oral
Subject Pitavastatin Small molecule 10 ug Oral
Subject Rosuvastatin Small molecule 50 ug Oral

Indications

No indication recorded.